[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621421":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":48,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Flurbiprofen patch combined with conventional therapy group","EXPERIMENTAL",null,[13],"Drug: Flurbiprofen patch combined with conventional therapy group",{"label":15,"type":16,"description":11,"interventionNames":17},"Conventional therapy group","ACTIVE_COMPARATOR",[18],"Drug: Conventional therapy group",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","In the flurbiprofen patch combined with conventional therapy group, apply the patch to the painful point near the herpes lesion. Use one patch per day, twice a day. In addition, the group will contain conventional treatment for HZ, except flurbiprofen patch, including opioids, antiviral drugs and so on.",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"In the conventional therapy group, treatments will include opioids, antiviral drugs and so on.",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Fang Luo","CONTACT","13611326978","13611326978@163.com",[34],{"facility":35,"status":36,"city":37,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Beijing Tiantan Hospital, Beijing, Beijing 100070","RECRUITING","Beijing","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"type":49,"investigatorFullName":29,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Director, Department of Pain Management, Principal Investigator, Clinical Professor","100621421","the-analgesic-efficacy-and-safety-of-flurbiprofen-patch-in-patients-with-herpes-zoster-100621421",false,"NCT07370402","The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Topical Patches (Flurbiprofen Patch) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of applying flurbiprofen patch;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the flurbiprofen patch;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding.","ALL","18 Years",{"count":61,"type":62},750,"ESTIMATED","INTERVENTIONAL",[65],"NA","Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Topical NSAIDs offer a promising alternative by delivering localized analgesia with reduced systemic exposure. Therefore, investigators hypothesize that flurbiprofen patch may effectively reduce the severity of HZ pain without significantly increasing adverse events.",[68,69],"Herpes Zoster","Pain","2026-01-22",{"date":72,"type":73},"2026-01-27","ACTUAL",{"date":75,"type":73},"2025-12-15",{"date":77,"type":62},"2027-12-31",{"name":5,"class":6},1]